IRIS Accounts Production v24.1.4.33 11419134 director 1.7.23 30.6.24 30.6.24 No description of principal activity 0 0 false true false false true true Ordinary 1.00000 iso4217:GBPiso4217:USDiso4217:EURxbrli:sharesxbrli:pureutr:tonnesutr:kWh114191342023-06-30114191342024-06-30114191342023-07-012024-06-30114191342022-06-30114191342022-07-012023-06-30114191342023-06-3011419134ns15:EnglandWales2023-07-012024-06-3011419134ns14:PoundSterling2023-07-012024-06-3011419134ns10:Director12023-07-012024-06-3011419134ns10:PrivateLimitedCompanyLtd2023-07-012024-06-3011419134ns10:SmallEntities2023-07-012024-06-3011419134ns10:AuditExempt-NoAccountantsReport2023-07-012024-06-3011419134ns10:SmallCompaniesRegimeForDirectorsReport2023-07-012024-06-3011419134ns10:SmallCompaniesRegimeForAccounts2023-07-012024-06-3011419134ns10:FullAccounts2023-07-012024-06-3011419134ns10:EntityHasNeverTraded2023-07-012024-06-3011419134ns10:OrdinaryShareClass12023-07-012024-06-3011419134ns10:RegisteredOffice2023-07-012024-06-3011419134ns5:CurrentFinancialInstruments2024-06-3011419134ns5:CurrentFinancialInstruments2023-06-3011419134ns5:ShareCapital2024-06-3011419134ns5:ShareCapital2023-06-3011419134ns5:CostValuation2023-06-3011419134ns10:OrdinaryShareClass12024-06-30
REGISTERED NUMBER: 11419134 (England and Wales)















Unaudited Financial Statements for the Year Ended 30 June 2024

for

Logixx Pharma Holding Group Limited

Logixx Pharma Holding Group Limited (Registered number: 11419134)






Contents of the Financial Statements
for the Year Ended 30 June 2024




Page

Company Information 1

Balance Sheet 2

Notes to the Financial Statements 3

Logixx Pharma Holding Group Limited

Company Information
for the Year Ended 30 June 2024







DIRECTOR: Mr M S Close





REGISTERED OFFICE: Merlin House
Brunel Road
Theale
Reading
Berkshire
RG7 4AB





REGISTERED NUMBER: 11419134 (England and Wales)

Logixx Pharma Holding Group Limited (Registered number: 11419134)

Balance Sheet
30 June 2024

2024 2023
Notes £    £    £    £   
FIXED ASSETS
Investments 4 578,875 578,875

CREDITORS
Amounts falling due within one year 5 577,875 577,875
NET CURRENT LIABILITIES (577,875 ) (577,875 )
TOTAL ASSETS LESS CURRENT
LIABILITIES

1,000

1,000

CAPITAL AND RESERVES
Called up share capital 6 1,000 1,000
SHAREHOLDERS' FUNDS 1,000 1,000

The company is entitled to exemption from audit under Section 480 of the Companies Act 2006 for the year ended 30 June 2024.

The members have not required the company to obtain an audit of its financial statements for the year ended 30 June 2024 in accordance with Section 476 of the Companies Act 2006.

The director acknowledges his responsibilities for:
(a)ensuring that the company keeps accounting records which comply with Sections 386 and 387 of the Companies Act 2006 and
(b)preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of each financial year and of its profit or loss for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the company.

The financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

In accordance with Section 444 of the Companies Act 2006, the Profit and Loss Account has not been delivered.

The financial statements were approved by the director and authorised for issue on 23 January 2025 and were signed by:





Mr M S Close - Director


Logixx Pharma Holding Group Limited (Registered number: 11419134)

Notes to the Financial Statements
for the Year Ended 30 June 2024

1. STATUTORY INFORMATION

Logixx Pharma Holding Group Limited is a private company, limited by shares , registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.

The presentation currency of the financial statements is the Pound Sterling (£).


2. ACCOUNTING POLICIES

Basis of preparing the financial statements
These financial statements have been prepared in accordance with Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" including the provisions of Section 1A "Small Entities" and the Companies Act 2006. The financial statements have been prepared under the historical cost convention.

These financial statements are prepared on the going concern basis.

Preparation of consolidated financial statements
The financial statements contain information about Logixx Pharma Holding Group Limited as an individual company and do not contain consolidated financial information as the parent of a group. The company is exempt under Section 399(2A) of the Companies Act 2006 from the requirements to prepare consolidated financial statements.

Investments in subsidiaries
Interests in subsidiaries, associates and jointly controlled entities are initially measured at cost and subsequently measured at cost less any accumulated impairment losses. The investments are assessed for impairment at each reporting date and any impairment losses or reversals of impairment losses are recognised immediately in profit or loss.

A subsidiary is an entity controlled by the company. Control is the power to govern the financial and operating policies of the entity so as to obtain benefits from its activities.

Logixx Pharma Holding Group Limited (Registered number: 11419134)

Notes to the Financial Statements - continued
for the Year Ended 30 June 2024

2. ACCOUNTING POLICIES - continued

Financial instruments
The company has elected to apply the provisions of Section 11 ‘Basic Financial Instruments’ and Section 12 ‘Other Financial Instruments Issues’ of FRS 102 to all of its financial instruments.

Financial instruments are recognised in the company's balance sheet when the company becomes party to the contractual provisions of the instrument.

Financial assets and liabilities are offset, with the net amounts presented in the financial statements, when there is a legally enforceable right to set off the recognised amounts and there is an intention to settle on a net basis or to realise the asset and settle the liability simultaneously.

Basic financial assets
Basic financial assets, which include debtors and cash and bank balances, are initially measured at transaction price including transaction costs and are subsequently carried at amortised cost using the effective interest method unless the arrangement constitutes a financing transaction, where the transaction is measured at the present value of the future receipts discounted at a market rate of interest. Financial assets classified as receivable within one year are not amortised.

Classification of financial liabilities
Financial liabilities and equity instruments are classified according to the substance of the contractual arrangements entered into. An equity instrument is any contract that evidences a residual interest in the assets of the company after deducting all of its liabilities.

Basic financial liabilities
Basic financial liabilities, including creditors, bank loans, loans from fellow group companies and preference shares that are classified as debt, are initially recognised at transaction price unless the arrangement constitutes a financing transaction, where the debt instrument is measured at the present value of the future payments discounted at a market rate of interest. Financial liabilities classified as payable within one year are not amortised.

Debt instruments are subsequently carried at amortised cost, using the effective interest rate method.

Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of business from suppliers. Amounts payable are classified as current liabilities if payment is due within one year or less. If not, they are presented as non-current liabilities. Trade creditors are recognised initially at transaction price and subsequently measured at amortised cost using the effective interest method.

Cash and cash equivalents
Cash and cash equivalents are basic financial assets and include cash in hand, deposits held at call with banks, other short-term liquid investments with original maturities of three months or less, and bank overdrafts. Bank overdrafts are shown within borrowings in current liabilities.

3. EMPLOYEES AND DIRECTORS

The average number of employees during the year was NIL (2023 - NIL).

Logixx Pharma Holding Group Limited (Registered number: 11419134)

Notes to the Financial Statements - continued
for the Year Ended 30 June 2024

4. FIXED ASSET INVESTMENTS
Shares in
group
companies
£   
Cost
At 1 July 2023
and 30 June 2024 578,875
Net book value
At 30 June 2024 578,875
At 30 June 2023 578,875

5. CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
2024 2023
£    £   
Amounts owed to group undertakings 577,875 577,875

6. CALLED UP SHARE CAPITAL

Allotted, issued and fully paid:
Number: Class: Nominal 2024 2023
value: £    £   
1,000 Ordinary £1 1,000 1,000

7. RELATED PARTY DISCLOSURES

The company has taken advantage of exemption, under the terms of Financial Reporting Standard 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland', not to disclose related party transactions with wholly-owned subsidiaries within the group.